Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018

Publisher Name :
Date: 20-Feb-2018
No. of pages: 46

According to the recently published report 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

The report 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Toxicology and Metabolic Disorders which include indications Short Bowel Syndrome, Chemotherapy Effects, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)

  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
Adocia SAS
Hanmi Pharmaceuticals Co Ltd
Naia Ltd
Shire Plc
Tasly Pharmaceutical Group Co Ltd
Zealand Pharma AS
Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
FE-203799 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15910 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPGG-72 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
Featured News & Press Releases
Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome
Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.
Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference
Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide
Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome
Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Adocia SAS, H1 2018
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Pipeline by Naia Ltd, H1 2018
Pipeline by Shire Plc, H1 2018
Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
Pipeline by Zealand Pharma AS, H1 2018
Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Mycoplasma Testing Market Insights, Forecast to 2025
    Published: 17-Jan-2019        Price: US 3900 Onwards        Pages: 116
    The major factors driving this market are the increasing growth of government support for pharmaceutical and biotechnology industries, rising R&D activities in life sciences research, and rising cell culture contamination. The Asia region is estimated to grow at the fastest rate which can be attributed to the increasing government investments in pharmaceutical R&D and the increasing trend of pharmaceutical outsourcing. The global Mycoplasma Testing market is valued at xx million US......
  • Global Mice Model Market Insights, Forecast to 2025
    Published: 16-Jan-2019        Price: US 4900 Onwards        Pages: 111
    Mice models are indispensable in research activities dealing with human disease processes due to striking similarities between the anatomy, physiology, and genetics of humans and mice. The major factor driving the growth of the market is the growing innovations and advances in mice models providing increased options to researchers to conduct research activities in particular diseases. The global Mice Model market is valued at xx million US$ in 2018 and will reach xx million US$ by ......
  • Global Label-Free Detection Market Size, Status and Forecast 2019-2025
    Published: 16-Jan-2019        Price: US 3900 Onwards        Pages: 91
    Innovations in label-free detection technologies, increasing drug discovery programs through research partnerships between pharmaceutical companies and academic institutes, and growth in the global pharmaceutical and biotechnology industries are expected to support market growth. Bio-layer Interferometry to register the highest CAGR during the forecast period. In 2018, the global Label-Free Detection market size was xx million US$ and it is expected to reach xx million US$ by the e......
  • Global Microfluidics Market Insights, Forecast to 2025
    Published: 16-Jan-2019        Price: US 4900 Onwards        Pages: 121
    Quick returns on investment coupled with the fast results and improved portability of the medical equipment embedded with microfluidics technology are the factors expected to drive the market during the forecast period. Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The global Microfluidics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The obj......
  • Global and Chinese Glycomics Industry, 2018 Market Research Report
    Published: 15-Jan-2019        Price: US 3000 Onwards        Pages: 140
    The 'Global and Chinese Glycomics Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Glycomics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Glycomics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, application......
  • Global and Chinese Separation Systems for Commercial Biotechnology Industry, 2018 Market Research Report
    Published: 15-Jan-2019        Price: US 3000 Onwards        Pages: 143
    The 'Global and Chinese Separation Systems for Commercial Biotechnology Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Separation Systems for Commercial Biotechnology industry with a focus on the Chinese market. The report provides key statistics on the market status of the Separation Systems for Commercial Biotechnology manufacturers and is a valuable source of guidance and direction for companies and individuals interested in......
  • Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 84
    "Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insight, 2019 - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insight, 2019 development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analys......
  • Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Wnt Signaling Pathway Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Wnt Signaling Pathway Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type......
  • Voltage-Dependent T-Type Calcium Channel Blockers - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 60
    "Voltage-Dependent T-Type Calcium Channel Blockers - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Voltage-Dependent T-Type Calcium Channel Blockers development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs